Pfizer (NYSE:PFE) Updates FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.800-3.000 for the period, compared to the consensus estimate of 3.090. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.9 billion.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Guggenheim raised their price target on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Bank of America lowered their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.22.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.02 on Tuesday. The firm has a market capitalization of $147.93 billion, a PE ratio of 15.14 and a beta of 0.46. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69. The business’s 50 day moving average is $25.12 and its 200-day moving average is $24.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is presently 100.00%.

Institutional Trading of Pfizer

Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC grew its position in Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after acquiring an additional 5,202,884 shares during the period. Amundi lifted its holdings in Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after purchasing an additional 4,043,413 shares during the last quarter. Caisse de depot et placement du Quebec grew its stake in Pfizer by 1,728.1% during the third quarter. Caisse de depot et placement du Quebec now owns 4,086,989 shares of the biopharmaceutical company’s stock worth $104,136,000 after buying an additional 3,863,424 shares during the last quarter. State Street Corp increased its holdings in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares in the last quarter. Finally, Unisphere Establishment raised its position in Pfizer by 13.8% in the 3rd quarter. Unisphere Establishment now owns 14,400,000 shares of the biopharmaceutical company’s stock valued at $366,912,000 after purchasing an additional 1,750,000 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.